A novel regimen of liposomal irinotecan plus capecitabine as total neoadjuvant therapy for locally advanced rectal cancer (LipCap): A phase II trial.

医学 伊立替康 卡培他滨 养生 内科学 临床终点 肿瘤科 结直肠癌 化疗 新辅助治疗 吉西他滨 临床研究阶段 不利影响 外科 临床试验 奥沙利铂 化疗方案 氟尿嘧啶 挽救疗法 入射(几何) 放化疗 前瞻性队列研究 完全响应
作者
Linlin Xiao,Fengpeng Wu
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (16_suppl)
标识
DOI:10.1200/jco.2026.44.16_suppl.e15640
摘要

e15640 Background: Clinical data on the participation of liposomal irinotecan in neoadjuvant therapy for locally advanced rectal cancer (LARC) is still limited worldwide. This prospective phase II trial aims to evaluate the efficacy and safety of liposomal irinotecan in this treatment field, with the goal of establishing a novel therapeutic option for LARC. Methods: Patients diagnosed with LARC (cT3-4NanyM0) were enrolled. Treatment commenced with long-course concurrent chemoradiotherapy (LCRT, 50.4Gy/28f). The concurrent chemotherapy regimen consisted of capecitabine (625 mg/m²bid on days of radiotherapy) and liposomal irinotecan (50 mg/m²on the first and 14th days of radiotherapy). After completing LCRT, consolidation chemotherapy comprising 4-6 cycles of liposomal irinotecan plus capecitabine was administered. The primary endpoint was the rate of pathological complete response (pCR). Secondary endpoints encompassed the rates of major pathological response (MPR) and clinical complete response (cCR), the incidence of adverse events (AEs), as well as 3-year progression-free survival and overall survival. The trial was registered with ClinicalTrials.gov (identifier: NCT06210971). Results: Between February 2024 and March 2025, 60 patients were enrolled and initiated neoadjuvant chemoradiotherapy. Of these, 57 proceeded to consolidation chemotherapy upon completion of the initial phase. Ultimately, 47 patients underwent surgical resection, all of whom achieved R0 resection. Pathological evaluation confirmed a pCR in 10 (21.3%) surgical patients and a MPR (defined as TRG 0–1) in 23 (48.9%). Among the 10 patients who did not undergo surgery, 3 achieved a cCR, resulting in an overall complete response rate (pCR + cCR) of 21.7% (13/60) for the entire cohort. The incidence of grade 3–4 AEs was 16.7%, with the most common being diarrhea (10.0%) and leukopenia (5.0%). Other notable AEs included anemia (3.3%), thrombocytopenia (1.7%), and neutropenia (0%). Conclusions: Combining a promising pathological response with a more manageable toxicity profile, this regimen offers a well-tolerated and effective alternative for TNT in LARC. Clinical trial information: NCT06210971 . Baseline characteristics of eligible patients. Characteristic Total (n = 60) Sex Male 44 (73.3%) Female 16 (26.7%) Age Median (Range) 60 (31-74) Clinical T stage cT3 46 (76.7%) cT4 14 (23.3%) Clinical N stage N0 3 (5%) N1 13 (21.7%) N2 44 (73.3%) Clinical stage II 3 (5%) III 57 (95%) Distance from primary tumor to anal verge ≤5cm 27 (45.0%) 5-10cm 33 (55.0%) EMVI Positive 19 (31.7%) Negative 41 (68.3%) MRF Positive 25 (41.7%) Negative 35 (58.3%)

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
佳佳发布了新的文献求助10
刚刚
1秒前
小蘑菇的应助被carbonhan采纳,获得10
1秒前
刘福生发布了新的文献求助10
1秒前
qqqq_8完成签到,获得积分10
1秒前
阿瑞发布了新的文献求助10
1秒前
1秒前
蓝意完成签到 ,获得积分20
2秒前
xy完成签到,获得积分20
2秒前
wu完成签到,获得积分10
2秒前
3秒前
zkylh的应助被汪琪琪儿采纳,获得10
4秒前
土豆完成签到,获得积分10
4秒前
既白发布了新的文献求助10
5秒前
爱上人家四月完成签到,获得积分10
5秒前
魏伯璋发布了新的文献求助10
5秒前
5秒前
5秒前
HapenLIAO发布了新的文献求助20
5秒前
Mxz完成签到,获得积分10
6秒前
6秒前
xy发布了新的文献求助15
6秒前
要减肥的书蕾完成签到,获得积分10
7秒前
小赵爱漂亮完成签到 ,获得积分10
7秒前
知还完成签到 ,获得积分10
7秒前
7秒前
嚣张贤王完成签到,获得积分10
7秒前
FashionBoy的应助被北北采纳,获得10
7秒前
8秒前
苏鸣雅发布了新的文献求助10
8秒前
UN完成签到,获得积分10
9秒前
9秒前
11秒前
11秒前
久某发布了新的文献求助10
11秒前
嘟噜发布了新的文献求助10
12秒前
12秒前
不想上班发布了新的文献求助10
12秒前
王饱饱发布了新的文献求助10
13秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178203
求助须知:如何正确求助?哪些是违规求助? 9568998
关于积分的说明 21802098
捐赠科研通 7773088
什么是DOI,文献DOI怎么找? 3432711
关于科研通互助平台的介绍 2556748
邀请新用户注册赠送积分活动 2478259